tiprankstipranks
Trending News
More News >
Calidi Biotherapeutics, Inc. (CLDI)
:CLDI
US Market

Calidi Biotherapeutics (CLDI) Price & Analysis

Compare
229 Followers

CLDI Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Clinical DataEarly clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.
Regulatory ApprovalThe FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).
Bears Say
Financial StabilityGiven the company's financial situation, even after the offering, there appears to be meaningful risk to the company continuing as a going concern.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

3.63%1.59%12.72%80.94%
12.72% Other Institutional Investors
80.94% Public Companies and Individual Investors

CLDI FAQ

What was Calidi Biotherapeutics, Inc.’s price range in the past 12 months?
Calidi Biotherapeutics, Inc. lowest stock price was $0.20 and its highest was $3.89 in the past 12 months.
    What is Calidi Biotherapeutics, Inc.’s market cap?
    Calidi Biotherapeutics, Inc.’s market cap is $7.11M.
      When is Calidi Biotherapeutics, Inc.’s upcoming earnings report date?
      Calidi Biotherapeutics, Inc.’s upcoming earnings report date is Aug 19, 2025 which is in 51 days.
        How were Calidi Biotherapeutics, Inc.’s earnings last quarter?
        Calidi Biotherapeutics, Inc. released its earnings results on May 14, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.18.
          Is Calidi Biotherapeutics, Inc. overvalued?
          According to Wall Street analysts Calidi Biotherapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Calidi Biotherapeutics, Inc. pay dividends?
            Calidi Biotherapeutics, Inc. does not currently pay dividends.
            What is Calidi Biotherapeutics, Inc.’s EPS estimate?
            Calidi Biotherapeutics, Inc.’s EPS estimate is -0.11.
              How many shares outstanding does Calidi Biotherapeutics, Inc. have?
              Calidi Biotherapeutics, Inc. has 31,792,580 shares outstanding.
                What happened to Calidi Biotherapeutics, Inc.’s price movement after its last earnings report?
                Calidi Biotherapeutics, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5%.
                  Which hedge fund is a major shareholder of Calidi Biotherapeutics, Inc.?
                  Currently, no hedge funds are holding shares in CLDI

                  Company Description

                  Calidi Biotherapeutics, Inc.

                  Calidi Biotherapeutics (CLDI) is a biotechnology company focusing on the development of innovative oncolytic virus-based therapies for cancer treatments. The company leverages proprietary technology platforms to enhance the therapeutic potential of oncolytic viruses, aiming to improve cancer treatment outcomes. Calidi Biotherapeutics operates within the biopharmaceutical sector, with its primary focus on developing immuno-oncology therapies targeting various cancer types.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Sensei Biotherapeutics
                  Bolt Biotherapeutics
                  SAB Biotherapeutics
                  Longeveron
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis